Immunic(IMUX) - 2023 Q4 - Annual Results

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update – Significantly Strengthened Balance Sheet in January 2024 with Execution of Three-Tranche Private Placement of up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025 Based on Initial$80 Million Tranche – – Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interim Analysis, Consistent Across the Entire Progressive Multiple Sclerosis Population and All Subtypes; Top-Line CA ...